INDIVIOR PLC(INDV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

INDV INDIVIOR PLC

Market Closed 06-18 16:00:00 EDT

38.30

+0.37

+0.98%

盘后37.50

-0.80-2.09%

19:59 EDT

High39.05	Low37.85	Vol4.28M
Open38.55	D1 Closing37.93	Amplitude3.15%
Mkt Cap4.67B	Tradable Cap3.98B	Total Shares121.92M
T/O163.81M	T/O Rate4.11%	Tradable Shares104.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"INDV","market":"US","secType":"STK","nameCN":"INDIVIOR PLC","latestPrice":38.3,"timestamp":1781812800000,"preClose":37.93,"halted":0,"volume":4276876,"hourTrading":{"tag":"盘后","latestPrice":37.5,"preClose":38.3,"latestTime":"19:59 EDT","volume":1458447,"amount":55857915.6956,"timestamp":1781827166323,"change":-0.8,"changeRate":-0.020888,"amplitude":0.020888},"delay":0,"changeRate":0.009754811494858883,"floatShares":104000000,"shares":121922058,"eps":0.981213,"marketStatus":"Market Closed","change":0.37,"latestTime":"06-18 16:00:00 EDT","open":38.55,"high":39.045,"low":37.85,"amount":163810509.50144,"amplitude":0.031505,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.981213,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1782115200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":37.93,"preHourTrading":{"tag":"盘前","latestPrice":38.77,"preClose":37.93,"latestTime":"09:28 EDT","volume":3208,"amount":122314.96084,"timestamp":1781789281225,"change":0.84,"changeRate":0.022146,"amplitude":0.024255},"postHourTrading":{"tag":"盘后","latestPrice":37.5,"preClose":38.3,"latestTime":"19:59 EDT","volume":1458447,"amount":55857915.6956,"timestamp":1781827166323,"change":-0.8,"changeRate":-0.020888,"amplitude":0.020888},"volumeRatio":3.36533100207929,"optionData":{"bulkOrders":[{"symbol":"INDV","call":false,"expireDate":1829019600000,"strike":"35.0","timestamp":1781798251518,"price":7.67,"volume":5000,"amount":3835000,"type":"+"},{"symbol":"INDV","call":true,"expireDate":1829019600000,"strike":"47.0","timestamp":1781798251518,"price":7.83,"volume":5000,"amount":3915000,"type":"-"}]},"impliedVol":0.3939,"impliedVolPercentile":0.1992},"requestUrl":"/m/hq/s/INDV/tweets","defaultTab":"tweets","newsList":[{"id":"2644824086","title":"Indivior Pharmaceuticals Initiated at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2644824086","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644824086?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:59","pubTimestamp":1781787540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/INDV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 18, 2026 08:59 ET (12:59 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INDV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644702777","title":"Indivior Pharmaceuticals, Inc :  Barclays Initiates Coverage With Overweight Rating  and Target Price $46","url":"https://stock-news.laohu8.com/highlight/detail?id=2644702777","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644702777?lang=en_us&edition=fundamental","pubTime":"2026-06-18 18:34","pubTimestamp":1781778860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nAZN4T2ZH1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","INDV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644702624","title":"Barclays Initiates Indivior at Overweight With $46 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2644702624","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644702624?lang=en_us&edition=fundamental","pubTime":"2026-06-18 18:21","pubTimestamp":1781778081,"startTime":"0","endTime":"0","summary":"Indivior (INDV) has an average rating of buy and mean price target of $50.83, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","INDV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644709323","title":"Indivior initiated with an Overweight at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2644709323","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644709323?lang=en_us&edition=fundamental","pubTime":"2026-06-18 16:45","pubTimestamp":1781772308,"startTime":"0","endTime":"0","summary":"Barclays initiated coverage of Indivior (INDV) with an Overweight rating and $46 price target The firm sees additional upside in the shares in fisc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/indivior-initiated-with-an-overweight-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/indivior-initiated-with-an-overweight-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","INDV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644877042","title":"U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis","url":"https://stock-news.laohu8.com/highlight/detail?id=2644877042","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644877042?lang=en_us&edition=fundamental","pubTime":"2026-06-18 15:14","pubTimestamp":1781766857,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Datadog, Jabil, PrologisJune 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Datadog, Jabil an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nL4N42Q0IZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DDOG","HIYY","INDV","ESS","HIMS","CME","CPT","INTU","MUU","ILMN","LU0342679015.USD","BIIB","PEP","HMYY","NUE","MAA","ANDE","MULL","LU2211815571.USD","JBL","TECH","LXP","DUK","FR","TXG","MU","PAYO","AHR","PK","NRIX","BTSG","HIMZ","LU2236285917.USD","EXR","CAG","EFSC","AJG","BDSX","BXP","DOGD","FROG","HIMY","KMX","LU1861215975.USD","EGP","EFX","MUD","EPRT","GRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643562765","title":"REFILE-FACTBOX-UK Market Exodus: Companies that moved away from London listing in recent years","url":"https://stock-news.laohu8.com/highlight/detail?id=2643562765","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643562765?lang=en_us&edition=fundamental","pubTime":"2026-06-16 22:54","pubTimestamp":1781621653,"startTime":"0","endTime":"0","summary":"REFILE-FACTBOX-UK Market Exodus: Companies that moved away from London listing in recent yearsCorrects hyperlink in third paragraph. Plumbing supplies distributor Ferguson FERG.N, FERG.L said on Tuesday it would cancel its secondary listing on the London Stock Exchange, days after betting giant Flutter Entertainment FLTRF.L said it would do the same, in the latest blow for the bourse.A growing number of companies have either shelved plans to list in London, exited the market altogether, or aimed to better capitalise on stronger foreign markets by demoting their London listing and upgrading their listings elsewhere., including easing rules for companies to raise funds, to boost the appeal of London as a global financial hub, amid investor pushback and post-Brexit-related challenges that have pressured UK market valuations.The company, which had a valuation of 34.06 billion as of June 15, had shifted its primary. COBALT: The Glencore-backed metals investor scrapped its plans for a London","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nL3N3S80KM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSFU","FERG.UK","03165","LU1868837300.USD","LU0792757196.USD","PHLLF","MSFY","IE00BGHQF631.EUR","MRSH","AZN.UK","WDS.AU","MSFX","SUNB","IE00BVYPNT70.USD","FLUT","LU1116320737.USD","CRH","FERG","LU1244550494.USD","MSFO","UIS","ULVR.UK","DEC.UK","MSFL","MSFW","LU1051770623.HKD","WSE","INDV","DEC","SG9999015978.USD","SG9999014575.USD","IE00B3T34201.USD","IE00BFXG0V08.USD","LU1150488135.SGD","GLEN.UK","LU0174119429.USD","LU1039938227.USD","LU0965509101.SGD","MSFT","LU1633808545.USD","LU2430703178.SGD","BHP.AU","MSFD","JTKWY","LU3187612489.SGD","LU2361044865.SGD","LU2229751404.USD","LU1599440770.SGD","LU2236285917.USD","LU0203347892.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643721888","title":"Indivior Chief Scientific Officer Christian Heidbreder disposes of 18,586 shares for $707,779.16","url":"https://stock-news.laohu8.com/highlight/detail?id=2643721888","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643721888?lang=en_us&edition=fundamental","pubTime":"2026-06-13 04:11","pubTimestamp":1781295108,"startTime":"0","endTime":"0","summary":"Indivior Pharmaceuticals Chief Scientific Officer Christian Heidbreder sold 18,586 common shares on June 11, 2026 at USD 38.06.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indivior Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 12, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDLbT0601:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Indivior Chief Scientific Officer Christian Heidbreder disposes of 18,586 shares for $707,779.16","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642426857","title":"UK Market Exodus: Companies that moved away from London listing in recent years","url":"https://stock-news.laohu8.com/highlight/detail?id=2642426857","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642426857?lang=en_us&edition=fundamental","pubTime":"2026-06-12 15:32","pubTimestamp":1781249544,"startTime":"0","endTime":"0","summary":"UK Market Exodus: Companies that moved away from London listing in recent yearsUpdates October 1, 2025 story to add Flutter and Magnum items. June 12  - FanDuel owner Flutter Entertainment FLTRF.L will delist from the London Stock Exchange in August, the company said on Friday, in the latest blow for the bourse.A growing number of companies have either shelved plans to list in London, exited the market altogether, or aimed to better capitalise on stronger foreign markets by demoting their London listing and upgrading their listings elsewhere. This trend is largely driven by investor pushback and post-Brexit-related challenges that have pressured UK market valuations.2026. ASTRAZENECA AZN.L: While the pharma giant and one of London's most valuable companies had said in September it was not exiting London, it did lay out plans to switch to a direct listing of its shares in the U.S.The company has a valuation of 173.21 billion, and many industry experts have warned that its move could pro","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nL3N3S80KM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0266013472.USD","IE00BKPKM643.USD","LU0612318971.USD","PHLLF","LU1228905037.USD","LU0171293334.USD","CRH","IE00BQXX3D17.EUR","LU2491050154.USD","MRSH","LU2237443382.USD","LU2357627491.SGD","AZN.UK","FERG","WDS.AU","SUNB","BK4007","UIS","BHP.AU","ULVR.UK","BK4588","LU0456854461.SGD","BK7095","LU0052756011.USD","SG9999001176.USD","LU2506951875.HKD","LU0289961442.SGD","LU0075056555.USD","LU1506573853.SGD","BK4134","LU0612318385.USD","LU1645745479.HKD","LU2041044095.USD","FLUT","LU2506952170.USD","INDV","LU1920062954.HKD","LU0882574055.USD","LU0289739343.SGD","WSE","DEC","LU0963555726.SGD","JTKWY","LU0211326839.USD","LU0757432116.USD","DEC.UK","LSEG.UK","03165","GLEN.UK","LU0630314457.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642447614","title":"Indivior CFO Ryan Preblick sells 36,000 shares for $1.36 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2642447614","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642447614?lang=en_us&edition=fundamental","pubTime":"2026-06-10 18:05","pubTimestamp":1781085927,"startTime":"0","endTime":"0","summary":"Indivior Pharmaceuticals CFO Ryan Preblick sold 36,000 common shares on June 8 at USD 37.7 each.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indivior Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDLGF9LS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Indivior CFO Ryan Preblick sells 36,000 shares for $1.36 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INDV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641161357","title":"Analysts Are Bullish on Top Healthcare Stocks: Elevance Health (ELV), Indivior (INDV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2641161357","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641161357?lang=en_us&edition=fundamental","pubTime":"2026-06-05 01:30","pubTimestamp":1780594209,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Elevance Health (ELV) and Indivior (INDV) with bulli...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-elevance-health-elv-indivior-indv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-elevance-health-elv-indivior-indv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0048573561.USD","BK4588","LU1670628061.USD","LU0957791311.USD","LU0985489474.SGD","LU0106261372.USD","ELV","LU0251142724.SGD","LU2237957811.SGD","LU0289739699.SGD","LU1720051017.SGD","SG9999003800.SGD","LU2244417387.USD","LU0251131958.USD","BK4154","LU0122379950.USD","LU0345770993.USD","LU0557290698.USD","LU2362541273.HKD","LU0433182093.SGD","LU0006306889.USD","LU2505996681.GBP","LU0314104364.USD","LU1548497426.USD","LU1506573853.SGD","LU0130517989.USD","LU2357305700.SGD","LU2430703095.HKD","LU0640476718.USD","LU0070302665.USD","LU2108987350.USD","LU0114720955.EUR","SG9999004303.SGD","LU0187121727.USD","LU0208291251.USD","LU0878866978.SGD","LU1280957306.USD","LU2505996509.AUD","SG9999011175.SGD","LU0477156953.USD","LU2237957902.USD","LU0314106906.USD","LU0742534661.SGD","LU0882574055.USD","LU0980610538.SGD","LU1720051108.HKD","INDV","LU1201861249.SGD","LU0170899867.USD","LU2592432038.USD","LU0320765489.SGD","LU1815333072.USD","SG9999001077.SGD","LU0345770308.USD","LU1670627923.USD","LU2430703251.USD","LU0061474960.USD","BK4007","LU2362540622.SGD","SGXZ23171101.USD","LU2430703178.SGD","BK4585","LU1489326972.SGD","LU1983299246.USD","LU0648001328.SGD","LU0266013472.USD","LU0130102774.USD","LU1023059063.AUD","LU0211331839.USD","LU2362541513.USD","LU0234570918.USD","LU0058720904.USD","LU0225283273.USD","LU0068578508.USD","LU1057294990.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637449322","title":"Will Real-World SUBLOCADE Adherence Data Reshape Indivior Pharmaceuticals' (INDV) Long-Acting OUD Treatment Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2637449322","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637449322?lang=en_us&edition=fundamental","pubTime":"2026-05-23 19:40","pubTimestamp":1779536446,"startTime":"0","endTime":"0","summary":"In May 2026, Indivior Pharmaceuticals reported two real-world evidence studies showing that adherence to its monthly injectable buprenorphine, SUBLOCADE, was associated with substantially lower relapse risk, fewer serious infections, and reduced healthcare utilization in people with opioid use disorder.\nBecause these analyses linked SUBLOCADE use to both clinical and healthcare resource benefits, they may strengthen the drug’s appeal to clinicians, payers, and treatment programs seeking more...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior-pharmaceuticals/news/will-real-world-sublocade-adherence-data-reshape-indivior-ph","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior-pharmaceuticals/news/will-real-world-sublocade-adherence-data-reshape-indivior-ph","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["INDV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637950319","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS), AbCellera Biologics (ABCL) and Indivior (INDV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2637950319","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637950319?lang=en_us&edition=fundamental","pubTime":"2026-05-22 19:40","pubTimestamp":1779450047,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Hims & Hers Health (HIMS), AbCellera Biologics (ABCL) and Indivio...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-hims-hers-health-hims-abcellera-biologics-abcl-and-indivior-indv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-hims-hers-health-hims-abcellera-biologics-abcl-and-indivior-indv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","INDV","BK4121","HIMY","BK4535","HIYY","ABCL","HIMS","HIMZ","BK4196","HMYY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636032847","title":"Indivior study links monthly injectable buprenorphine adherence to lower opioid relapse risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2636032847","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636032847?lang=en_us&edition=fundamental","pubTime":"2026-05-20 21:04","pubTimestamp":1779282282,"startTime":"0","endTime":"0","summary":"Indivior disclosed results from two retrospective real-world studies that have already been published, linking adherence to its monthly injectable buprenorphine  to improved outcomes in opioid use disorder.In a claims-based analysis, patients who stayed on the monthly injection showed a lower likelihood of returning to opioid use than patients on other medication-assisted treatment approaches.A separate cohort study found patients on the monthly injection had fewer serious infection complications than those treated with daily oral buprenorphine.The same analysis also associated the monthly injection with reduced use of inpatient care, emergency departments, and outpatient services, pointing to potential payer and provider cost implications.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL2SqKMJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","SG9999014021.USD","SG9999014039.USD","LU0314104364.USD","BK4007","INDV","BK4112","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BK4585","NDAQ","IE00BGHQF748.EUR","LU2095319765.USD","IE00BKPKM429.USD","BK4588","LU2210149790.SGD","IE00BN0W2W23.USD","SG9999014013.SGD","LU2210150020.SGD","SG9999014005.SGD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636153538","title":"Indivior’s Earnings Call Highlights SUBLOCADE-Driven Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2636153538","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636153538?lang=en_us&edition=fundamental","pubTime":"2026-05-20 14:17","pubTimestamp":1779257864,"startTime":"0","endTime":"0","summary":"Indivior PLC (($INDV)) has held its Q1 earnings call. Read on for the main highlights of the call. Indivior PLC struck an upbeat tone on its latest...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/indiviors-earnings-call-highlights-sublocade-driven-surge?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/indiviors-earnings-call-highlights-sublocade-driven-surge?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INDV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636557568","title":"Lifeward names Keith D. Rose chief medical officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2636557568","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636557568?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:06","pubTimestamp":1779192419,"startTime":"0","endTime":"0","summary":"Rose previously served as vice president, medical affairs and medical director, neurosciences at the company.His prior senior roles included medical affairs and clinical leadership positions at Biocodex, Novocure, Ipsen Bioscience, Jazz Pharmaceuticals, and Indivior.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL318mJB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LFWD","LU0320765992.SGD","BK4604","LU0109394709.USD","LU0154245756.USD","BK4548","LU0823416689.USD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","BK4533","NVCR","IE00BKPKM429.USD","NDAQ","SG9999014039.USD","BK4534","BK4082","LU0154245673.USD","LU2210150020.SGD","LU2095319765.USD","LU0314104364.USD","BK4007","LU0889565916.HKD","SG9999014013.SGD","IE00BN0W2T93.GBP","BK4585","SG9999014021.USD","INDV","LU2210149790.SGD","BK4532","IE00BN0W2W23.USD","BK4588","JAZZ","BK4112","SG9999014005.SGD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635851053","title":"Indivior Eliminates Chief Scientific Officer Role, Realigns Leadership","url":"https://stock-news.laohu8.com/highlight/detail?id=2635851053","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635851053?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:20","pubTimestamp":1778880007,"startTime":"0","endTime":"0","summary":"Indivior ( ($INDV) ) has provided an announcement. Indivior Pharmaceuticals, Inc. will eliminate the role of Chief Scientific Officer effective Jun...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/indivior-eliminates-chief-scientific-officer-role-realigns-leadership?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/indivior-eliminates-chief-scientific-officer-role-realigns-leadership?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INDV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635037596","title":"Indivior eliminates chief scientific officer role; Heidbreder departs end-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635037596","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635037596?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:04","pubTimestamp":1778875472,"startTime":"0","endTime":"0","summary":"Indivior will eliminate Chief Scientific Officer role effective June 1, 2026.Christian Heidbreder will continue reporting to CEO in advisory role on special projects through end of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indivior Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 15, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL4FlQyp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INDV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635037557","title":"Indivior Pharmaceuticals Inc - to Eliminate Chief Scientific Officer Position Effective June 1, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2635037557","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635037557?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:04","pubTimestamp":1778875448,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nFWN41S14V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","INDV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633901252","title":"Indivior Pharmaceuticals, Inc : Stifel Raises Target Price to $52 From $42","url":"https://stock-news.laohu8.com/highlight/detail?id=2633901252","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633901252?lang=en_us&edition=fundamental","pubTime":"2026-05-06 15:16","pubTimestamp":1778051794,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nFWN41J0DL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INDV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633911857","title":"A Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Q1 Beat, Raised 2026 Guidance And Buyback News","url":"https://stock-news.laohu8.com/highlight/detail?id=2633911857","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633911857?lang=en_us&edition=fundamental","pubTime":"2026-05-05 18:23","pubTimestamp":1777976589,"startTime":"0","endTime":"0","summary":"Indivior Pharmaceuticals (INDV) is back on investors' radars after a busy stretch that combined strong Q1 2026 results, a raised full year revenue outlook, and a fresh accelerated share repurchase plan.\nSee our latest analysis for Indivior Pharmaceuticals.\nThe recent Q1 beat, raised 2026 guidance, and the new accelerated share repurchase agreement have all coincided with strong momentum, with a 27.93% 1 month share price return and a very large 1 year total shareholder return that far...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior-pharmaceuticals/news/a-look-at-indivior-pharmaceuticals-nasdaqgsindv-valuation-af-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior-pharmaceuticals/news/a-look-at-indivior-pharmaceuticals-nasdaqgsindv-valuation-af-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["INDV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.indivior.com","stockEarnings":[{"period":"1week","weight":0.0045},{"period":"1month","weight":0.0354},{"period":"3month","weight":0.3072},{"period":"6month","weight":0.0878},{"period":"1year","weight":1.7554},{"period":"ytd","weight":0.0674}],"compareEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.1514},{"period":"6month","weight":0.0972},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.0951}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet. The company operates in approximately 40 countries worldwide. It has collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.","yearOnYearQuotes":[{"month":1,"riseRate":0.583333,"avgChangeRate":0.021864},{"month":2,"riseRate":0.583333,"avgChangeRate":0.011788},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.007447},{"month":4,"riseRate":0.833333,"avgChangeRate":0.037804},{"month":5,"riseRate":0.833333,"avgChangeRate":0.065087},{"month":6,"riseRate":0.5,"avgChangeRate":0.054075},{"month":7,"riseRate":0.8,"avgChangeRate":0.171847},{"month":8,"riseRate":0.545455,"avgChangeRate":-0.014379},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.095405},{"month":10,"riseRate":0.363636,"avgChangeRate":0.007009},{"month":11,"riseRate":0.545455,"avgChangeRate":0.010295},{"month":12,"riseRate":0.636364,"avgChangeRate":0.020229}],"exchange":"NASDAQ","name":"INDIVIOR PLC","nameEN":"INDIVIOR PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"INDIVIOR PLC(INDV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest INDIVIOR PLC(INDV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"INDIVIOR PLC,INDV,INDIVIOR PLC股票,INDIVIOR PLC股票老虎,INDIVIOR PLC股票老虎国际,INDIVIOR PLC行情,INDIVIOR PLC股票行情,INDIVIOR PLC股价,INDIVIOR PLC股市,INDIVIOR PLC股票价格,INDIVIOR PLC股票交易,INDIVIOR PLC股票购买,INDIVIOR PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"INDIVIOR PLC(INDV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest INDIVIOR PLC(INDV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}